Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment source : Ir.kalvista.com save search
KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema
Published: 2022-10-04 (Crawled : 11:00) - ir.kalvista.com
KALV | News | $11.21 -2.01% -2.05% 190K
|
Health Technology
|
| O: -50.91%
H: 8.15%
C: -16.31%
kvd824 treatment pharmaceuticals trial phase 2 hereditary angioedema
KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients
Published: 2022-02-28 (Crawled : 16:20) - ir.kalvista.com
KALV | News | $11.21 -2.01% -2.05% 190K
|
Health Technology
|
| O: -0.62%
H: 2.63%
C: -0.06%
kvd900 treatment als
KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE
Published: 2021-11-08 (Crawled : 12:00) - ir.kalvista.com
KALV | News | $11.21 -2.01% -2.05% 190K
|
Health Technology
|
| O: 1.83%
H: 0.0%
C: -2.51%
treatment ema
KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema
Published: 2021-08-23 (Crawled : 11:00) - ir.kalvista.com
KALV | News | $11.21 -2.01% -2.05% 190K
|
Health Technology
|
| O: 2.65%
H: 5.79%
C: 5.47%
treatment phase 2 kvd824 trial hereditary angioedema
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop
Published: 2021-06-05 (Crawled : 20:20) - ir.kalvista.com
KALV | News | $11.21 -2.01% -2.05% 190K
|
Health Technology
| Email alert
Add to watchlist
treatment phase 2
KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop
Published: 2021-05-10 (Crawled : 11:00) - ir.kalvista.com
KALV | News | $11.21 -2.01% -2.05% 190K
|
Health Technology
|
| O: -1.23%
H: 0.12%
C: -1.04%
treatment hereditary angioedema
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.